Who is likely to benefit from statin therapy?

Individuals with clinical evidence of atherosclerotic cardiovascular disease (ASCVD) are indeed the primary beneficiaries of statin therapy. Statins are effective in reducing LDL cholesterol levels and have been shown to lower the risk of cardiovascular events such as heart attacks and strokes in patients who have already experienced these issues. The mechanism of action includes not just lowering cholesterol but also improving endothelial function and stabilizing atherosclerotic plaques.

In clinical guidelines, statin therapy is often recommended for those with established ASCVD due to the substantial evidence supporting its benefits in this population. This includes individuals who have had a history of myocardial infarction, unstable angina, coronary artery procedures, or peripheral artery disease.

The other options do not align with the established guidelines for statin therapy. Individuals under 40 with low cholesterol generally do not meet the criteria for statin initiation. Those with only high triglycerides, without other risk factors or ASCVD, may not necessarily derive the same benefits from statins as those with confirmed ASCVD. Lastly, individuals with no cardiovascular risk factors are unlikely to require statin therapy as there is insufficient evidence to support its use in this group. Therefore, the most appropriate choice for likely beneficiaries of statin therapy is those with clinical evidence of ASC